Mylan Seeks Approval for Generic Advair Diskus

Article

Mylan has submitted an abbreviated new drug application to the FDA for a generic equivalent to GlaxoSmithKline's Advair Diskus.

Mylan has submitted an abbreviated new drug application to the FDA for a generic equivalent to GlaxoSmithKline’s Advair Diskus.

If approved, Mylan would be able to manufacture and market fluticasone propionate 100, 250, and 500 mcg and salmeterol 50 mcg inhalation powder.

Advair Diskus is currently indicated for patients 4 years and older who have asthma or who need maintenance treatment of airflow obstruction.

Advair Diskus can also reduce exacerbations for patients with chronic obstructive pulmonary disease.

The most common adverse effects from using the Advair Diskus product include upper respiratory tract infection, throat irritation, and voice hoarseness. In some cases, it may also lead to fungal infections in the mouth or throat, pneumonia, a weakening of the immune system, or reduced adrenal function.

Related Videos
Image credit:  Gorodenkoff | stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.